Targovax has been granted up to 12.6 MNOK (2.3 MUSD) from the Norwegian Research council’s BIA-programme in competition with high quality projects across all industries. The project focuses on good and improved formulations of TG01 with adjuvant.
The grant is announced just after a capital increase in the company, securing 7.5 MNOK (1.4 MUSD) from The Radium Hospital Research Foundation, Algot Ivest, Trygve Schiørbeck, and new and existing owners. A further 12.5 MNOK is committed from current owners.
Press release (English, Norwegian)
Clinical study: (in Norwegian, OUS Radiumhospitalet), (in English, Nordic NECT)